The approval was based on data from the POETYK PsA-1 and POETYK PsA-2 trials, which evaluated the efficacy and safety of deucravacitinib in adults aged 18 years and older with active PsA.
In this video, Leilani Alvarez, DVM, DACVSMR, CVA, CCRT, head of the Integrative and Rehabilitative Medicine Department at the Schwarzman Animal Medical Center in New York, New York, discusses the ...
Regulatory expansion positions deucravacitinib 6 mg once daily as a first-in-class oral TYK2 option for active PsA, complementing its prior plaque psoriasis indication. POETYK PsA-1 showed significant ...
The FDA has approved deucravacitinib for adults with active psoriatic arthritis, according to a press release from Bristol ...
Developers of gene therapies to treat knee osteoarthritis are taking the familiar intra-articular route to deliver proteins and molecules directly to the site of the disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results